CA3064291A1 - Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure - Google Patents

Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure Download PDF

Info

Publication number
CA3064291A1
CA3064291A1 CA3064291A CA3064291A CA3064291A1 CA 3064291 A1 CA3064291 A1 CA 3064291A1 CA 3064291 A CA3064291 A CA 3064291A CA 3064291 A CA3064291 A CA 3064291A CA 3064291 A1 CA3064291 A1 CA 3064291A1
Authority
CA
Canada
Prior art keywords
compound
heart failure
treatment
heart
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3064291A
Other languages
English (en)
French (fr)
Inventor
Jacek Ostrowski
Ricardo Garcia
Nicholas R. Wurtz
Nancy Leigh Carson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62567841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3064291(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CA3064291A1 publication Critical patent/CA3064291A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3064291A 2017-05-22 2018-05-22 Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure Pending CA3064291A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762509489P 2017-05-22 2017-05-22
US62/509,489 2017-05-22
PCT/US2018/033783 WO2018217684A1 (en) 2017-05-22 2018-05-22 Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure

Publications (1)

Publication Number Publication Date
CA3064291A1 true CA3064291A1 (en) 2018-11-29

Family

ID=62567841

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3064291A Pending CA3064291A1 (en) 2017-05-22 2018-05-22 Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure

Country Status (15)

Country Link
US (1) US20200069644A1 (enExample)
EP (1) EP3630097A1 (enExample)
JP (1) JP2020520948A (enExample)
KR (1) KR20200006595A (enExample)
CN (1) CN110662538A (enExample)
AU (1) AU2018273382A1 (enExample)
BR (1) BR112019024185A2 (enExample)
CA (1) CA3064291A1 (enExample)
CL (1) CL2019003325A1 (enExample)
CO (1) CO2019013015A2 (enExample)
EA (1) EA201992704A1 (enExample)
IL (1) IL270749A (enExample)
MX (1) MX2019013926A (enExample)
PE (1) PE20200402A1 (enExample)
WO (1) WO2018217684A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2869129T3 (es) * 2017-06-09 2021-10-25 Bristol Myers Squibb Co Agonistas de piperidinona del receptor 2 de péptidos formilados
JP7700210B2 (ja) 2020-07-09 2025-06-30 ブリストル－マイヤーズ スクイブ カンパニー ピラゾロンホルミルペプチド２受容体アゴニスト
JP7802765B2 (ja) 2020-08-12 2026-01-20 ブリストル－マイヤーズ スクイブ カンパニー オキソピロリジン尿素ｆｐｒ２アゴニスト
KR20230084530A (ko) * 2020-10-09 2023-06-13 브리스톨-마이어스 스큅 컴퍼니 아미노이미다졸 fpr2 효능제
CN119055775A (zh) * 2022-07-30 2024-12-03 中国医学科学院阜外医院 Jun抑制剂在制备用于治疗射血分数保留的心衰的药物中的用途
CN118831080B (zh) * 2024-09-24 2024-11-22 上海交通大学医学院附属仁济医院 5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1492552A2 (en) * 2002-04-03 2005-01-05 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
NZ752095A (en) 2013-11-28 2022-07-01 Kyorin Seiyaku Kk Urea derivative or pharmacologically acceptable salt thereof
KR101645015B1 (ko) * 2014-03-11 2016-08-03 포항공과대학교 산학협력단 Fpr2를 활성화하는 물질을 포함하는, 인슐린 저항성 관련 질환 치료용 조성물

Also Published As

Publication number Publication date
WO2018217684A1 (en) 2018-11-29
AU2018273382A1 (en) 2020-01-16
US20200069644A1 (en) 2020-03-05
CL2019003325A1 (es) 2020-04-17
PE20200402A1 (es) 2020-02-26
CN110662538A (zh) 2020-01-07
IL270749A (en) 2020-01-30
CO2019013015A2 (es) 2020-01-17
EP3630097A1 (en) 2020-04-08
EA201992704A1 (ru) 2020-03-19
BR112019024185A2 (pt) 2020-06-02
MX2019013926A (es) 2020-01-20
KR20200006595A (ko) 2020-01-20
JP2020520948A (ja) 2020-07-16

Similar Documents

Publication Publication Date Title
US20200069644A1 (en) Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure
KR102200176B1 (ko) 신규 방법
EP3645002B1 (en) Methods of treating heart failure with cardiac sarcomere activators
Maier et al. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study
EP1572196B1 (en) Combination of a dpp-iv inhibitor and a ppar-alpha compound
RU2362555C2 (ru) Применение замещенных цианопирролидинов и содержащих их комбинированных препаратов для лечения гиперлипидемии и ассоциированных заболеваний
JP2022523645A (ja) ミトコンドリアミオパチーの処置におけるＰＰＡＲδアゴニストの使用
JP2002128696A (ja) 肺高血圧の治療
SG11202108508RA (en) Use of a ppar-delta agonist in the treatment of fatty acid oxidation disorders (faod)
US20240277698A1 (en) Methods of using aldosterone synthase inhibitors
ZA200503542B (en) Pharmaceutical combination of telmisartan and atovastatin for the prophylaxis of treatment of cardiovascular, cardiopulmonary, pulmanory or renal diseases
US20240148735A1 (en) Methods of treating heart failure with vibegron
JP6688503B2 (ja) 医薬用組成物
US20240366596A1 (en) Treatment of hfpef in post-menopausal women with an sgc stimulator
SK19332001A3 (sk) Použitie antagonistov kortizolu v liečení srdcového zlyhania
US12419863B2 (en) Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy
CA3257284A1 (en) ADDRESSING FEEDBACK TO THE INJECTION SITE ASSOCIATED WITH THE ADMINISTRATION OF ELAMIPRETIDE
JP2005531492A (ja) 高リスク患者のｉｉ型糖尿病を低減させる方法
US20070032557A1 (en) Method for administering levosimendan
KR20190043076A (ko) 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제
JP2004339218A (ja) 有機化合物の使用
WO2026050494A1 (en) Omecamtiv mecarbil for use in treating heart failure by activating cardiac sarcomere
Coleman et al. Antihypertensive drugs
WO2023200738A1 (en) Combination treatment of dilated cardiomyopathy comprising a tyrosine kinase inhibitor and a statin
US20230381190A1 (en) Methods and Treatment for Complex Lymphatic Malformations